36,373 Shares in Pfizer Inc. $PFE Acquired by AGP Franklin LLC

AGP Franklin LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 36,373 shares of the biopharmaceutical company’s stock, valued at approximately $906,000.

Several other hedge funds also recently modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC grew its stake in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after purchasing an additional 6,045,763 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. AQR Capital Management LLC lifted its stake in Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the last quarter. Finally, Amundi lifted its stake in Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after purchasing an additional 4,043,413 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.6%

NYSE PFE opened at $26.65 on Friday. The firm’s 50 day moving average price is $27.24 and its two-hundred day moving average price is $26.06. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a twelve month low of $21.97 and a twelve month high of $28.75. The stock has a market cap of $151.53 billion, a price-to-earnings ratio of 19.59 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the firm posted $0.63 earnings per share. Pfizer’s revenue was down 1.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 126.47%.

Analyst Ratings Changes

Several research firms have issued reports on PFE. UBS Group lifted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Bank of America reduced their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, CICC Research assumed coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.48.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China pre-orders and commercialization progress for Pfizer’s GLP-1 weight‑management drug (Xianweiying) increase near‑term revenue optionality in a large market and validate the obesity franchise expansion. China pre-order Reuters
• Positive Sentiment: PF-08653944 (GLP‑1) continues to show promise — Phase 2b data supporting a once‑monthly dosing profile and a program threaded into >20 obesity trials (10 Phase 3 targeted in 2026) point to a potential multi‑year growth engine beyond legacy COVID products. Yahoo GLP-1 article
• Positive Sentiment: Advances in early‑stage programs: completion of a Phase 1 heart‑failure study in China and launches/advances for PF‑08653944 liver and obesity gastric‑emptying studies broaden pipeline visibility and create long‑term optionality if later‑stage data succeed. Heart failure Phase 1 Liver study Gastric emptying study
• Positive Sentiment: Dividend: Pfizer declared a $0.43 quarterly dividend (350th consecutive quarter), which supports yield‑seeking investors and underpins the stock’s income appeal. Dividend press release
• Neutral Sentiment: New Phase 1 cancer trial start and upcoming ASCO oncology presentations add potential upside if data impress, but early‑stage readouts are uncertain and timing is multi‑quarter. New Phase 1 cancer trial ASCO preview
• Neutral Sentiment: Consensus analyst view remains mixed/neutral (consensus “Hold”), leaving the stock sensitive to headline catalysts and quarter‑to‑quarter beats. Analyst consensus
• Negative Sentiment: Pipeline pruning: Pfizer ended a Phase 1 cancer trial — a near‑term negative for oncology optionality and a reminder that not all internal programs will reach later stages. Trial termination
• Negative Sentiment: Analyst downgrades/pressure: Barclays reiterated a “sell” and RBC/others issued underperform ratings — these views can drive short‑term selling and weigh on investor sentiment. Barclays sell note RBC underperform
• Negative Sentiment: Recent coverage noted the stock has recently fallen on mixed headlines and earnings‑cycle positioning, reflecting a market focus on near‑term growth vs. long‑term pipeline bets. Stock sinks article

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.